Baricitinib Completed Phase 3 Trials for Atopic Dermatitis (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03334396A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT03334422Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT03733301A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis